Amivantamab
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Amivantamab (coding:ncit:C124993)
RxNorm: amivantamab (coding:rxcui:2549199, coding:omop:1536935)
SNOMED: Amivantamab (coding:sctid:1162751008, coding:omop:37160574)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) HC (1) | EGFR Exon 20 (Insertion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| FDA (1) HC (1) | EGFR Exon 20 (Insertion) | Non-Small Cell Lung Cancer | Amivantamab | |
| FDA (2) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| FDA (2) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed |